Retrograde Colonic Irrigation to Manage Spina Bifida Functional Digestive Sequelae: a Multicenter, Prospective, Randomized Controlled Trial (IRRICO)

May 22, 2023 updated by: Rennes University Hospital

Spina Bifida is a developmental congenital disorder caused by the incomplete closing of the embryonic neural tube, leading to serious malformations of the nervous system. Caudal neuropore malformations almost always lead to sensory-motor deficits (including complete paraplegia) with orthopedic deformations, pressure sores, and pelvic/perineal neurological dysfunctions (affecting the bladder-sphincter, anorectal, and genital sphere).

The purpose of the study is to assess the efficacy of retrograde colonic irrigation associated with usual care (medical treatments, patient education) on anorectal dysfunction (incontinence and/or constipation), compared to usual care only.

Study Overview

Status

Completed

Conditions

Detailed Description

Sphincter dysfunctions impair the quality of life and patients' self-esteem. However, defecation disorders are important issues the Spina Bifida National Reference Center has to deal with. Indeed, more than half of patients are concerned. These disorders are mainly due to fecal stasis. Treatments include laxatives and hygiene recommendations. Colonic irrigation can also be useful, especially to achieve colonic vacuity and improve continence. The use of intra-rectal balloon inflation probes and the control of instillation flow improved retrograde colonic irrigation efficacy. Nevertheless, this technique is currently not evaluated in young adults suffering from Spina Bifida functional digestive sequelae, who are mainly concerned by Malone enema.

The purpose of the study is to assess the efficacy of retrograde colonic irrigation associated with usual care (medical treatments, patient education) on anorectal dysfunction (incontinence and/or constipation), compared to usual care only.

Study Type

Interventional

Enrollment (Actual)

34

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

      • Lille, France, 59037
        • CHRU de Lille
      • Nantes, France, 44093
        • CHU de Nantes
      • Ploemeur, France, 56275
        • CMRRF de Kerpape
      • Rennes, France, 35000
        • Rennes University Hospital
      • Rouen, France, 76031
        • CHU de Rouen
      • Vandoeuvre les Nancy, France, 54511
        • CHRU de Nancy-Brabois

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

15 years and older (Child, Adult, Older Adult)

Accepts Healthy Volunteers

No

Description

Inclusion Criteria:

  • Patients aging at least 15 years old with Spina Bifida neurological pelvi-perineal sequelae, objected by neurologic exam , functional urinary and/or anorectal and/or neurophysiological data,
  • Patients with NBD score above 9,
  • Written and informed consent (Minor children may be included with the consent of the two parents).

Exclusion Criteria:

  • Patients with psychiatric disorders, cognitive or intellectual disabilities compromising the assessment of primary outcome measure,
  • Patients using currently irrigation colonic technique,
  • Patients with functional colostomy, known anal or colorectal stenosis, colorectal cancer, acute or chronic inflammatory disease, recent anal or colorectal surgery for less than 3 months, polyp removal for less than 4 weeks, ischemic colitis.
  • Patients with urinary trophic or orthopedic disease with planned surgery during inclusion or follow-up periods,
  • Patients with progressive anal disease (suppuration, hemorrhoid or rectal prolapse)
  • Patient with a hard follow-up ( judged by the investigator)
  • Person involved in another clinical trial
  • Pregnant women
  • Person with a measure of legal protection (guardianship)

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: None (Open Label)

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: Retrograde Colonic Irrigation with usual care
In the experimental group, retrograde colonic irrigation sessions will be scheduled in addition to conventional treatment according to a progressive volume program.
Active Comparator: Usual Care
In the comparator group, patients will receive conventional care, according to each clinical center habits.

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Time Frame
Neurogenic Bowel Dysfunction (NBD) score
Time Frame: Ten weeks after inclusion
Ten weeks after inclusion

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Questionnaire data of incontinence and constipation (Cleveland scores)
Time Frame: Ten weeks after inclusion
Ten weeks after inclusion
Questionnaire data of incontinence and constipation (Cleveland scores)
Time Frame: Twenty-four weeks after inclusion
Twenty-four weeks after inclusion
Quality of life
Time Frame: Ten weeks after inclusion
Quality of life will be assess by semi-quantified scales
Ten weeks after inclusion
Quality of life
Time Frame: Twenty-four weeks after inclusion
Quality of life will be assess by semi-quantified scales
Twenty-four weeks after inclusion
Self esteem (Rosenberg scale)
Time Frame: Ten weeks after inclusion
Ten weeks after inclusion
Functional digestive score (NBD)
Time Frame: Twenty-four weeks after inclusion
Twenty-four weeks after inclusion
Cumulative time spent using restrooms
Time Frame: Ten weeks after inclusion
Cumulative time spent using restrooms will be collected with a patient reported outcome questionnaire
Ten weeks after inclusion
Cumulative time spent using restrooms
Time Frame: Twenty-four weeks after inclusion
Cumulative time spent using restrooms will be collected with a patient reported outcome questionnaire
Twenty-four weeks after inclusion
Number of accidents of incontinence
Time Frame: Ten weeks after inclusion
Number of accidents of incontinence will be collected with a patient reported outcome questionnaire
Ten weeks after inclusion
Number of accidents of incontinence
Time Frame: Twenty-four weeks after inclusion
Number of accidents of incontinence will be collected with a patient reported outcome questionnaire
Twenty-four weeks after inclusion
Number of incontinence guards used
Time Frame: Ten weeks after inclusion
Number of incontinence guards used will be collected with a patient reported outcome questionnaire
Ten weeks after inclusion
Number of incontinence guards used
Time Frame: Twenty-four weeks after inclusion
Number of incontinence guards used will be collected with a patient reported outcome questionnaire
Twenty-four weeks after inclusion
Type of incontinence guards used
Time Frame: Ten weeks after inclusion
Type of incontinence guards (panty liner, pad, nappy) used will be collected with a patient reported outcome questionnaire
Ten weeks after inclusion
Type of incontinence guards used
Time Frame: Twenty-four weeks after inclusion
Type of incontinence guards (panty liner, pad, nappy) used will be collected with a patient reported outcome questionnaire
Twenty-four weeks after inclusion
Number of stools
Time Frame: Ten weeks after inclusion
Number of stools will be collected with a patient reported outcome questionnaire
Ten weeks after inclusion
Number of stools
Time Frame: Twenty-four weeks after inclusion
Number of stools will be collected with a patient reported outcome questionnaire
Twenty-four weeks after inclusion
Stools consistency
Time Frame: Ten weeks after inclusion
Stools consistency will be collected with a patient reported outcome questionnaire
Ten weeks after inclusion
Stools consistency
Time Frame: Twenty-four weeks after inclusion
Stools consistency will be collected with a patient reported outcome questionnaire
Twenty-four weeks after inclusion
Symptoms experienced during defecation
Time Frame: Ten weeks after inclusion
Symptoms experienced during defecation will be collected with a patient reported outcome questionnaire
Ten weeks after inclusion
Symptoms experienced during defecation
Time Frame: Twenty-four weeks after inclusion
Symptoms experienced during defecation will be collected with a patient reported outcome questionnaire
Twenty-four weeks after inclusion
Frequency of digital help during defecation
Time Frame: Ten weeks after inclusion
The frequency of digital stimulation will be collected with a patient reported outcome questionnaire
Ten weeks after inclusion
Frequency of digital help during defecation
Time Frame: Twenty-four weeks after inclusion
The frequency of digital stimulation will be collected with a patient reported outcome questionnaire
Twenty-four weeks after inclusion

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Investigators

  • Principal Investigator: Laurent Siproudhis, Md, PhD, Rennes University Hospital

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

March 16, 2015

Primary Completion (Actual)

July 31, 2019

Study Completion (Actual)

July 31, 2019

Study Registration Dates

First Submitted

February 2, 2015

First Submitted That Met QC Criteria

February 6, 2015

First Posted (Estimate)

February 11, 2015

Study Record Updates

Last Update Posted (Actual)

May 24, 2023

Last Update Submitted That Met QC Criteria

May 22, 2023

Last Verified

May 1, 2023

More Information

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Spina Bifida

Clinical Trials on Usual Care

3
Subscribe